Firefly Neuroscience, Inc. (AIFF) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Firefly Neuroscience, Inc. is an artificial intelligence company developing medical devices and software for high-resolution visualization of neuro-physiological interconnections. The company operates a vertically integrated platform (Firefly Platform) and commercially deploys the FDA-cleared Evoke EEG System. As of June 30, 2026, the system was active in over 85 clinical sites in the United States. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $514,000 | $999,000 |
| Gross Profit | $253,000 | $474,000 |
| Gross Margin | 49.2% | 47.4% |
| Operating Loss | $(1,974,000) | $(3,984,000) |
| Net Loss | $(1,984,000) | $(3,988,000) |
| Cash and Cash Equivalents (End of Period) | $9,226,000 | |
| Net Cash Used in Operating Activities (6mo) | $(3,698,000) | |
| Net Cash Provided by Financing Activities (6mo) | $10,277,000 | |
| Accumulated Deficit | $(115,558,000) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 72% quarter-over-quarter (Q2 2026 vs. Q2 2025) and 192% year-to-date, primarily driven by the acquisition of Evoke Neuroscience, Inc. in April 2025.
- Cost of Goods Sold (COGS): COGS rose significantly to $261,000 in Q2 2026 from $25,000 in Q2 2025, reflecting material costs for Evoke's Versus products and new customer success staffing.
- Operating Expenses: Total operating expenses increased to $2,227,000 in Q2 2026 from $1,908,000 in Q2 2025. Research and Development (R&D) expenses rose 56% due to product development spending. General and Administrative (G&A) expenses increased 11% largely due to bonus expenses.
- Other Income/Expense: The company reported a significant improvement in "Other Income (Expense)" compared to the prior year, which was heavily impacted by a $9.4 million loss on derivative fair value and a $1.4 million loss on debt settlement in the first half of 2025. No such non-cash charges occurred in the first half of 2026.
- Liquidity: Cash balances increased from $2.7 million at year-end 2025 to $9.2 million at June 30, 2026, following a private placement raising approximately $10.25 million in gross proceeds.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern within one year. This is due to recurring losses, an accumulated deficit of $115.6 million, and negative operating cash flows. Management plans to address this through expense management, commercial expansion, and additional equity financing.
- Capital Raising: The company raised $10.277 million in net proceeds during the six months ended June 30, 2026, via a private placement of units (Initial and Additional Closings). An At-The-Market (ATM) offering agreement with up to $7.4 million capacity was established in February 2026, but no shares had been sold under this agreement as of June 30, 2026.
- Internal Controls: Management concluded that internal controls over financial reporting were not effective as of June 30, 2026, citing material weaknesses in Information Technology General Controls (ITGCs) and a lack of segregation of duties. Remediation is expected to be completed by Q4 2026.
- Contingencies: The company has a contingent royalty commitment to the Israel Innovation Authority (IIA) of approximately $5.9 million, payable as 3.0% of sales of products developed with IIA grants. No liability has been recognized as the outcome is contingent on commercial feasibility.
- Geopolitical Risks: The filing highlights risks related to conflicts involving Israel, the United States, and Iran, as well as trade tariffs, which could impact operations and costs.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $9.2 million cash balance against the burn rate of ~$3.7 million per six months to assess the timeline for the next capital raise.
- Revenue Quality: Confirm the sustainability of the 192% revenue growth and the extent to which it is driven by the Evoke acquisition versus organic growth of the Firefly platform.
- Internal Control Remediation: Monitor the progress of remediation for the material weaknesses in ITGCs and segregation of duties, as failure to fix these could impact future reporting reliability.
- Dilution Risk: Review the terms of the outstanding warrants (14.6 million warrants outstanding) and the potential dilution from the ATM program and future private placements required to fund operations.
- Going Concern Status: Assess the likelihood of the company securing additional funding on favorable terms given the explicit "substantial doubt" disclosure.